| (EUR) | Dec 2025 | Y/Y change |
|---|---|---|
| Revenue | 13.04B | 38.42% |
| Operating expense | — | — |
| Net income | 813.57M | -959.72% |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, 6IB.F returned +0.2% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +31.6% |
| 1 year | +0.2% |
| 5 years | +73.7% |
| All-time high | €11.80 (Jan 2021) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in 6IB.F would be worth today ›No. Innovent Biologics, Inc. has not paid a dividend in the past 12 months.
Innovent Biologics, Inc. is part of the Healthcare sector.
Innovent Biologics, Inc. has a market cap of 19.36B EUR, based on the latest quote.
Innovent Biologics, Inc. is scheduled to report earnings on Aug 25, 2026.
